Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (24444)	8/13/1998 1:13:00 PM
From: Mudcat	Read Replies (1) \| Respond to of 32384

<Instead of shelling out $75 million for Seragen, Ligand could've taken a substantial amount of money from Lilly. They chose Seragen instead.> Just my point, they made a huge mistake, they should have taken the payment from Lilly.

To: Machaon who wrote (24444)	8/13/1998 1:25:00 PM
From: Mudcat	Read Replies (2) \| Respond to of 32384

<How about the average cost of getting a drug approved by the FDA? Industry wide, the average cost of a drug getting approved is $1 billion dollars> The $1B figure is misleading as are most of your posts. The $1B is for drugs with large clinical populations that require long Phase III trials and has nothing to do with drugs SRGN or LGND are developing for small populations. You yourself just said SRGN spent $200M on R&D and let me remind you not all of it was for ONTAK. Do you think Lgnd will spend $1B on Panretin? I sure hope not. I still think Lgnd overpaid for ONTAK. Unless you know of other ONTAK off label uses or if any other of SRGN's research is worth anything then they overpaid. I believe Robinson even stated that ONTAK was the only SRGN science that was of value to Lgnd.